CML cells incubated in low oxygen were treated with the MCT inhibitors bindarit or syrosingopine, to maintain the intracellular concentration of lactate at high levels, and with the selective LDH‐B inhibitor AXKO‐0046, to inhibit lactate conversion to pyruvate, or the MPC inhibitor UK‐5099, to block the entry of pyruvate into mitochondria, or Devimistat, an agent able to inhibit two key TCA cycle enzymes, PDH and α‐ketoglutarate dehydrogenase. The gene discussed is LDHB; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.